Call Now

Mouse CD137 / 4-1BB / TNFRSF9 Protein (Fc Tag)

4-1BB,A930040I11Rik,AA408498,AI325004,Cd137,CDw137,ILA,Ly63

Catalog Number P50811-M02H
Organism Species Mouse
Host Human Cells
Synonyms 4-1BB,A930040I11Rik,AA408498,AI325004,Cd137,CDw137,ILA,Ly63
Molecular Weight The secreted recombinant mouse TNFRSF9/Fc is a disulfide-linked homodimer. The reduced monomer comprises 429 amino acids and has a calculated molecular mass of 47 kDa. As a result of glycosylation, the apparent molecular mass of the monomer is approximately 65-75 kDa in SDS-PAGE under reducing conditions.
predicted N Val 24
SDS-PAGE
Purity > 90 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the mouse TNFRSF9 (NP_001070976.1) (Met 1-Leu 211) was fused with the Fc region of human IgG1 at the C-terminus.
Bio-activity Measured by its binding ability in a functional ELISA.
Immobilized mouse His-TNFSF9 (P50067-M07H) at 10 μg/ml (100 μl/well) can bind mouse TNFRSF9-Fc, The EC50 of mouse TNFRSF9-Fc is 12.0-29.0 ng/ml.
Research Area Cardiovascular |Angiogenesis |Cytokine & Receptor |Tumor Necrosis Factor & Receptor |TNF receptor
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.
Reference
  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.